Related Experiment Video
Updated: Jan 11, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
2.2K
Mesothelioma in Situ With a TP53 Mutation
Andrew Churg1, Erika Haase2, Raheela Siddiqui3
1Department of Pathology, Vancouver General Hospital, and University of British Columbia, Vancouver, BC, Canada.
The American Journal of Surgical Pathology
|November 12, 2025
Summary
This study details a rare peritoneal mesothelioma case linked to a TP53 gene deletion. P53 overexpression suggests its potential role in diagnosing mesothelioma in situ.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Mesothelioma in situ (MIA) is a precursor to invasive mesothelioma.
- Most MIA cases feature BAP1 mutations.
- The genetic landscape of MIA is not fully understood.
Purpose of the Study:
- To report a unique case of MIA progressing to invasive mesothelioma.
- To investigate the genetic alterations associated with this specific MIA case.
- To explore the potential diagnostic utility of p53 in MIA.
Main Methods:
- Case study of a 55-year-old male patient.
- Immunohistochemistry for BAP1, MTAP, NF2/merlin, and p53.
- Analysis of a long in-frame TP53 deletion.
Main Results:
- The patient presented with peritoneal mesothelioma.
- Immunohistochemistry revealed retained BAP1, MTAP, and NF2/merlin.
- Overexpression of p53 was observed in MIA and invasive mesothelioma.
- A long in-frame TP53 deletion was identified.
Conclusions:
- This is the first reported case of MIA associated with a TP53 mutation.
- TP53 alterations may play a role in MIA development and progression.
- p53 immunohistochemistry may aid in the diagnosis of mesothelioma in situ.
